Low-Dose of Intrapulmonary Pirfenidone Improves Human Transforming Growth Factorβ1-Driven Lung Fibrosis

Aschner, Y. and Downey, G. P. (2016). Transforming Growth Factor-β: Master

Regulator of the Respiratory System in Health and Diseasemaster regulator of

the respiratory system in Health and disease. Am. J. Respir. Cell Mol. Biol. 54,

647–655. doi:10.1165/rcmb.2015-0391tr

Barratt, S. L., Creamer, A., Hayton, C., and Chaudhuri, N. (2018). Idiopathic

pulmonary fibrosis (IPF): an overview. J. Clin. Med. 7, 201. doi:10.3390/

jcm7080201

Bayat, M. and Cook, A. M. (2004). Intrapulmonary administration of medications.

J. Neurosci. Nurs. 36, 231–235. doi:10.1097/01376517-200408000-00012

Caja, L., Dituri, F., Mancarella, S., Caballero-Diaz, D., Moustakas, A., Giannelli, G.,

et al. (2018). TGF-beta and the tissue microenvironment: relevance in fibrosis

and cancer. Int. J. Mol. Sci. 19, 1294. doi:10.3390/ijms19051294

Choi, K, Lee, K, Ryu, S. W., Im, M, Kook, K. H., and Choi, C (2012). Pirfenidone

inhibits transforming growth factor-β1-induced fibrogenesis by blocking

nuclear translocation of Smads in human retinal pigment epithelial cell line

ARPE-19. Mol. Vis. 18, 1010–1020.

Costabel, U., Albera, C., Lancaster, L. H., Lin, C.-Y., Hormel, P., Hulter, H. N., and

Noble, P. W. (2017). An open-label study of the long-term safety of pirfenidone

in patients with idiopathic pulmonary fibrosis (RECAP). Respiration 94,

408–415. doi:10.1159/000479976

D’Alessandro-Gabazza, C. N., Kobayashi, T., Boveda-Ruiz, D., Takagi, T., Toda,

M., Gil-Bernabe, P., et al. (2012). Development and preclinical efficacy of novel

transforming growth factor-β1 short interfering RNAs for pulmonary fibrosis.

Am. J. Respir. Cell Mol. Biol. 46, 397–406. doi:10.1165/rcmb.2011-0158oc

D’Alessandro-Gabazza, C. N., Kobayashi, T, Yasuma, T, Toda, M, Kim, H,

Fujimoto, H, et al. (2020). A staphylococcus pro-apoptotic peptide induces

acute exacerbation of pulmonary fibrosis. Nat. Commun. 11, 1539. doi:10.1038/

s41467-020-15344-3

D’alessandro-Gabazza, C. N., Mendez-Garcia, C., Hataji, O., Westergaar, S.,

Watanabe, F., Yasuma, T., et al. (2018). Identification of halophilic microbes

in lung fibrotic tissue by oligotyping. Front. Microbiol. 9, 1892. doi:10.3389/

fmicb.2018.01892

Drumm, M. L., Konstan, M. W., Schluchter, M. D., Handler, A., Pace, R., Zou, F.,

et al. (2005). Genetic modifiers of lung disease in cystic fibrosis. N. Engl. J. Med.

353, 1443–1453. doi:10.1056/nejmoa051469

Du, Y., Zhu, P., Wang, X., Mu, M., Li, H., Gao, Y., et al. (2020). Pirfenidone

alleviates lipopolysaccharide-induced lung injury by accentuating BAP31

regulation of ER stress and mitochondrial injury. Journal of Autoimmunity

112, 102464. doi:10.1016/j.jaut.2020.102464

Fujiwara, K., Kobayashi, T., Fujimoto, H., Nakahara, H., D’Alessandro-Gabazza, C.

N., Hinneh, J. A., et al. (2017). Inhibition of cell apoptosis and amelioration of

pulmonary fibrosis by thrombomodulin. TAm. J. Clin. Pathol. 187, 2312–2322.

doi:10.1016/j.ajpath.2017.06.013

Hisatomi, K., Mukae, H., Sakamoto, N., Ishimatsu, Y., Kakugawa, T., Hara, S., et al.

(2012). Pirfenidone inhibits TGF-beta1-induced over-expression of collagen

type I and heat shock protein 47 in A549 cells. BMC Pulm. Med. 12, 24. doi:10.

1186/1471-2466-12-24

Iwata, T., Yoshino, I., Yoshida, S., Ikeda, N., Tsuboi, M., Asato, Y., et al. (2016). A

phase II trial evaluating the efficacy and safety of perioperative pirfenidone for

prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung

cancer patients undergoing pulmonary resection: oest Japan Oncology Group

6711 L (PEOPLE Study). Respir. Res. 17, 90. doi:10.1186/s12931-016-0398-4

Iyer, S. N., Gurujeyalakshmi, G., and Giri, S. N. (1999). Effects of pirfenidone on

transforming growth factor-beta gene expression at the transcriptional level in

bleomycin hamster model of lung fibrosis. J. Pharmacol. Exp. Therapeut. 291, 367–373

Katzenstein, A.-L. A. and Myers, J. L. (1998). Idiopathic pulmonary fibrosis. Am.

J. Respir. Crit. Care Med. 157, 1301–1315. doi:10.1164/ajrccm.157.4.9707039

Khoo, J. K., Montgomery, A. B., Otto, K. L., Surber, M., Faggian, J., Lickliter, J. D.,

et al. (2020). A randomized, double-blinded, placebo-controlled, doseescalation phase 1 study of aerosolized pirfenidone delivered via the pari

investigational eflow nebulizer in volunteers and patients with idiopathic

pulmonary fibrosis. J. Aerosol. Med. Pulm. Drug. Deliv 33, 15–20. doi:10.

1089/jamp.2018.1507

King, T. E., Jr., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I.,

Glassberg, M. K., et al. (2014a). A phase 3 trial of pirfenidone in patients with

Frontiers in Pharmacology | www.frontiersin.org

12

November 2020 | Volume 11 | Article 593620

Okano et al.

Intrapulmonary Pirfenidone for Pulmonary Fibrosis

present manuscript, and SI and HS are employees from Shionogi & Co., Ltd. ECG

and TK have a patent on the mouse used in this study.

Urawa, M., Kobayashi, T., D’Alessandro-Gabazza, C. N., Fujimoto, H., Toda, M.,

Roeen, Z., et al. (2016). Protein S is protective in pulmonary fibrosis. J Thromb

Haemost 14, 1588–1599. doi:10.1111/jth.13362

Wolters, P. J., Collard, H. R., and Jones, K. D. (2014). Pathogenesis of idiopathic

pulmonary fibrosis. Annu. Rev. Pathol. Mech. Dis. 9, 157–179. doi:10.1146/

annurev-pathol-012513-104706

Wu, J., Chen, H., Wu, J.-H., Zhoul, S.-C., and Zeng, F.-D. (2014). Effect of

pirfenidone on activity of hepatic cytochrome P450 in rats. Herald of

Medicine 33, 723–726.

Yu, J., Zhou, Z., Tay-Sontheimer, J., Levy, R. H., and Ragueneau-Majlessi, I. (2018).

Risk of clinically relevant pharmacokinetic-based drug-drug interactions with

drugs approved by the U.S. Food and drug administration between 2013 and

2016. Drug Metab. Dispos. 46, 835–845. doi:10.1124/dmd.117.078691

The remaining authors declare that the research was conducted in the absence of

any commercial or financial relationships that could be construed as a potential

conflict of interest.

Copyright © 2020 Okano, Kobayashi, Yasuma, D’alessandro-Gabazza, Toda,

Fujimoto, Nakahara, Okano, Takeshita, Nishihama, Tomaru, Fridman

D’alessandro, Ishida, Sugimoto, Takei and Gabazza. This is an open-access

article distributed under the terms of the Creative Commons Attribution License

(CC BY). The use, distribution or reproduction in other forums is permitted,

provided the original author(s) and the copyright owner(s) are credited and that

the original publication in this journal is cited, in accordance with accepted academic

practice. No use, distribution or reproduction is permitted which does not comply

with these terms.

Conflict of Interest: ECG, CND-G, and TY have received a grant from Shionogi

Co. to support in part the execution of the experimental study reported in the

Frontiers in Pharmacology | www.frontiersin.org

13

November 2020 | Volume 11 | Article 593620

...